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Abstract
Background: Inflammatory arthritis (IA), including rheumatoid arthritis (RA), ankylosing spondylitis (AS) and psoriatic
arthritis (PsA), leads to increased cardiovascular disease occurrence probably due to atherosclerosis. One of the first
stages in atherogenesis is endothelial dysfunction (ED). Therefore, we aimed to compare endothelial function (EF) in
patients with IA, and to examine the effects of methotrexate (MTX) monotherapy and antitumor necrosis factor
(anti-TNF) treatment with or without MTX comedication (anti-TNF ± MTX) on EF.
Methods: From the PSARA observational study, all patients with RA (n = 64), PsA (n = 29), and AS (n = 20) were
evaluated for EF. In patients with ED at baseline (n = 40), we evaluated changes in the Reactive Hyperemic Index
(RHI) after 6 weeks and 6 months of antirheumatic therapy.
Results: In IA patients with ED, RHI significantly improved after 6 weeks (p < 0.001) and 6 months (p < 0.001) of
treatment, independent of changes in disease activity parameters. After 6 months, RHI had improved more in the
MTX group than in the anti-TNF ± MTX group, and the difference remained statistically significant after adjustments
for potential confounders. Among patients with active RA, AS, and PsA, those with AS appeared to have the worst
endothelial function, although they were the youngest.
Conclusion: Treatment with MTX and anti-TNF ± MTX was associated with a relatively fast improvement of EF in IA
patients with ED, independent of change in disease activity. Therefore, modes of action other than the anti-
inflammatory effect may contribute to the EF improvement. After 6 months, the EF improvement was more
pronounced in the MTX group than in the anti-TNF ± MTX group.
Trial registration: Clinicaltrials, NCT00902005. Registered on 13 May 2009.
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Background
Inflammatory arthritis (IA), including rheumatoid arthritis
(RA), ankylosing spondylitis (AS), and psoriatic arthritis
(PsA), has increased cardiovascular (CV) morbidity and
mortality, probably due to cardiovascular disease (CVD)
caused by atherosclerosis [1–5]. The first step in the
development of atherosclerosis is endothelial dysfunction
(ED) which is initially a reversible process [6]. Thus, im-
proving endothelial function (EF) might be of great im-
portance in preventing atherosclerosis. The endothelium
has several vital homeostatic functions, including regula-
tion of vascular tone and growth, thrombogenesis and
thrombolysis, and interactions between platelets and leu-
kocytes and the vessel wall. The endothelium secretes
vasorelaxing (e.g., nitric oxide) and vasoconstricting (e.g.,
endothelin-1) substances in response to mechanical stress
[6, 7]. ED is characterized by impaired ability of the artery
to dilate in response to physical and chemical stimuli [8, 9].
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Assessment of EF has been used to estimate the CV risk in
IA patients [10, 11].
Clinical studies indicate that antirheumatic treatment,
including methotrexate (MTX) and antitumor necrosis
factor (anti-TNF) treatment, not only ameliorates disease
activity but also reduces CV morbidity and mortality in
RA patients [12, 13]. There is also evidence that anti-
TNF treatment improves EF in RA, and reduces arterial
stiffness and intima-media thickness in patients with
RA, PsA, and AS [14, 15].
However, information on the effect of antirheumatic
drugs on EF in AS and PsA patients is still limited.
Therefore, the aim of this study was to compare EF in
RA, AS, and PsA patients, and to examine the effect of
antirheumatic treatment (MTX and/or anti-TNF) on EF
in these patient groups.
Methods
Patients
We examined patients from the PSoriatic arthritis,
Ankylosing spondylitis, Rheumatoid Arthritis (PSARA)
study who completed 6 months of follow-up and in
whom EF was measured (n = 113). Of the 114 patients
who completed the study, one PsA patient was excluded
because she was not able to adhere to the requirements
of the EF measurement (smoked and did not sit still).
All patients in PSARA, an observational study, had been
included at the Lillehammer Hospital for Rheumatic
Diseases as described elsewhere [16]. Briefly, the inclusion
criteria were: males and females with an age range 18–80
years; and PsA according to the Moll and Wright 1973 cri-
teria [17], AS according to the modified New York diag-
nostic criteria for AS [18], or RA according to the ACR
1987 criteria [19], and clinical indication for starting with
either MTX monotherapy or anti-TNF treatment with or
without MTX comedication (anti-TNF ±MTX).
Exclusion criteria included lack of cooperability, any
contraindication for MTX and anti-TNF, any significant
infection (including subclinical tuberculosis), pregnancy
or breastfeeding, congestive heart failure, use of systemic
glucocorticoids > 10 mg/day during the last 2 weeks or
anti-TNF during the last 4 weeks before the inclusion,
and any chronic inflammatory disease other than RA,
AS, or PsA.
All patients were Caucasian and were examined at
baseline and after 6 weeks and 6 months of treatment.
Treatment
Patients were either treated with MTX monotherapy or
with anti-TNF ±MTX. The type and doses of antirheu-
matic treatment were decided by rheumatologists not in-
volved in the study upon clinical judgment and in
accordance with Norwegian guidelines. Doses were as
follows: etanercept 50 mg subcutaneous injection once a
week; infliximab 3–5 mg/kg intravenous injection at
baseline, then following standard dosing regimen; adali-
mumab 40 mg subcutaneous injection every other week;
MTX 15–25 mg orally once a week.
Norwegian guidelines consider MTX as a first-line anti-
rheumatic treatment in patients with chronic peripheral
arthritis, in particular RA [20]. Due to limited effects of
conventional disease-modifying antirheumatic drugs
(DMARDs) in axial spondyloarthritis (SpA), including AS
and PsA, TNF inhibition is used in SpA patients with axial
disease who do not sufficiently respond to nonsteroidal
anti-inflammatory drugs (NSAIDs) [21, 22]. Throughout
the study period, patients using glucocorticoids were kept
on a steady dose (10 mg or less per day).
Clinical and laboratory tests
Data collection included demographic data, medical history,
physical findings, lifestyle information and medication.
EF was examined, and blood samples were drawn after
fasting for 8 h (including nonallowance of smoking), and
hospital routine blood tests were consecutively performed.
EF was evaluated using a reactive hyperemia peripheral
arterial tonometry (RH-PAT) examination which evaluates
the overall health of the endothelium by measurment of
finger arterial pulsatile volume changes as described previ-
ously [23]. The Reactive Hyperemic Index (RHI) was
calculated as the ratio between the magnitude of the aver-
age postobstructive pulse wave amplitude (PWA) and the
average of baseline PWA (preocclusion). ED was defined
as RHI ≤ 1.67 as recommended by the manufacturer and
in accordance with findings from a population at risk for
ischemic heart disease [23]. RHI results for a subgroup of
our RA sample have been published previously [24].
We evaluated improvement in RHI only in patients
with ED, as a significant improvement in RHI could not
be expected in patients with normal EF.
Statistics
For comparisons of continuous independent variables
between and within the examined groups, nonparamet-
ric tests (Mann-Whitney U test and Wilcoxon sign test)
were applied, since the continuous variables of interest
were not normally distributed (according to normality
plots). For comparison of categorical data between the
study groups, the Chi-square test was used. Linear
regression analyses were used to assess associations be-
tween RHI change modeled as the dependent variable
(baseline and 6 months) and selected disease activity
markers. Age, gender, rheumatic diagnosis, and variables
that showed a significant association with the dependent
variable in simple regression analyses were included in
multiple linear regression models.
P values ≤ 0.05 were considered statistically significant,
and all statistical tests were two-sided. Our analyses
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were considered exploratory so no correction for
multiple testing was performed.




Baseline clinical and cardiovascular characteristics of all
patients who completed the 6 months of follow-up are
described in Tables 1 and 2.
The anti-TNF ±MTX and MTX groups had similar
characteristics except for a significantly shorter rheum-
atic disease duration and higher Physicians' Global
Assessment (PGA) score in the MTX group (p = 0.043
and p = 0.002, respectively). The proportion of patients
with ED was similar in both treatment groups.
Although patients with AS were the youngest (statisti-
cally significantly younger than the RA group), they had
higher frequency of ED, angina pectoris, myocardial
infarction, and use of some cardiovascular drugs (beta
blockers, statins and warfarin) compared to the RA and
PsA groups (these differences did not reach the level of
statistical significance).
The AS group had the lowest median RHI value, which
was significantly different from the PsA group (p = 0.040;
Fig. 1). The proportion of women was highest in the RA
group and lowest in the AS group (Table 1).
When evaluating only patients with ED, there were no
statistically significant differences in RHI baseline values
between any of the three diagnostic groups.
RHI improvement in patients with ED
In the total IA group with ED (n = 40), RHI significantly
improved from baseline to 6 weeks (RHI6weeks = 1.86, p
< 0.001), and from baseline to 6 months (RHI6months =
1.80, p < 0.001) (Fig. 1). RHI baseline levels are described
in Table 2.
The RHI improvement was most pronounced at
6 weeks. At 6 months, the RHI median level slightly, but
statistically nonsignificantly, decreased again (Fig. 1).
In analyses of all three diagnostic groups with ED, only
RA patients showed statistically significant RHI im-
provement from baseline to 6 weeks (RHI at 6 weeks =
1.96, p < 0.001) and baseline to 6 months (RHI at
6 months = 1.86, p = 0.001; Fig. 1). The PsA group
showed RHI improvement at both visits (RHI at 6 weeks =
1.67 and RHI at 6 months = 1.80). In the AS group the RHI
levels slightly decreased from baseline to 6 weeks (RHI at
6 weeks = 1.50). However, after 6 months of treatment, the
RHI levels increased again (RHI at 6 months = 1.68). None
of the RHI changes in the PsA and AS groups reached
statistical significance.
Effect of MTX and anti-TNF ± MTX on RHI in patients
with ED
In both treatment groups, RHI significantly improved at
both follow-up visits compared to baseline (MTX: base-
line to 6 weeks p = 0.002, baseline to 6 months p = 0.001;
anti-TNF ±MTX: baseline to 6 weeks p = 0.004, baseline
to 6 months p = 0.024). After 6 months of treatment,
RHI values in the MTX group continued to increase
compared to 6 weeks. However, in the anti-TNF ±MTX
group RHI values at 6 months were lower than at 6 weeks,
resulting in a statistically significant difference in RHI
values between the two groups at 6 months (Fig. 2).
Within the RA and PsA groups there were no signifi-
cant differences in RHI between patients treated with
MTX and anti-TNF ±MTX.
Linear regression analysis
Our data did not reveal any statistically significant asso-
ciations between RHI and inflammatory markers, includ-
ing C-reactive protein (CRP), white blood cell (WBC)
count, erythrocyte sedimentation rate (ESR), pentraxin
(PTX)3, Modified Health Assessment Questionnaire
(MHAQ), PGA, or Patients' Global Assessment Score of
Disease Activity (PtGA), at baseline (data not shown).
In simple regression analyses, only female gender and
rheumatic disease duration were significantly related to
RHI change from baseline to 6 months, while age, IA
diagnosis, changes in markers of IA activity and severity
(CRP, WBC count, ESR, PTX3, MHAQ, PGA, and
PtGA) (Table 3), traditional CV risk factors (smoking,
hypertension, diabetes, body mass index, established
CVD (history of previous myocardial infarctions and
presence of angina) and medications (statins, angiotensin
converting enzyme inhibitors, and calcium antagonists);
data not shown) were not.
Female gender was related to a greater improvement in
RHI compared to male gender, and the association
remained statistically significant in several multiple regres-
sion models including models adjusted for age, rheumatic
disease duration, and IA diagnosis. Rheumatic disease dur-
ation was negatively related to RHI change from baseline
to 6 months and it stayed statistically significant in several
multiple regression models (adjusted for age, gender, and
IA diagnosis and age, gender, and treatment).
The difference in RHI change from baseline to
6 months between the MTX group and the anti-TNF ±
MTX group remained statistically significant after
adjustments for age, female gender, rheumatic disease
duration, and IA diagnosis (Table 3).
Corrections for baseline RHI values
In analyses adjusted for baseline RHI values, MTX was
associated with a greater improvement in RHI than anti-
TNF ±MTX after 6 months in patients with ED (p = 0.007).
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The RHI change from baseline to 6 months was not
related to RHI baseline values in patients with ED.
RHI mean values in patients with normal EF did not
change at any of the control points of time (data not shown).
Discussion
To our knowledge, this is the first study to compare the
effect of MTX monotherapy and anti-TNF ±MTX
treatment on EF in IA patients, and to compare levels of
RHI between RA, PsA, and AS patients with active
disease.
In IA patients with ED, antirheumatic treatment
was associated with improvement in EF both at
6 weeks and 6 months of follow-up compared to
baseline. However, after 6 weeks, EF continued to im-
prove only in the MTX group.











Age (years) 57 (28–79) 50 (23–78)¥ 49 (30–72)ф 56 (28–79) 55 (23–75)
Women, n (%) 47 (73) 12 (41)¥ 4 (20)ɸ€ 30 (61) 33 (52)
Rheumatic disease duration (years) 2 (0–30) 3 (0–37) 3 (0–40) 0.10 (0–25) 3.7 (0–40)*
Disease activity
CRP (mg/L) 8 (1–78) 5 (1–99) 10 (1–157) 8 (1–99) 6.5 (1–157)
ESR (mm/h) 18.5 (1–81) 7 (2–48)¥ 9.5 (2–87)ɸ 14 (1–81) 13 (2–87)
Anti-CCP, n (%) 39 (61) – – 17 (35) 22(34)
Rheumatoid factor IgA, n (%) 32 (50) – – 15 (31) 17 (27)
Rheumatoid factor IgM, n (%) 45 (70) – – 22(45) 23(36)
BASDAI – 4.73 (0.3–9.5) 5.1 (0.9–9.6) 5.5 (0.3–9.3) 5.1 (0.9–9.7)
BASFI – 3.2(0–9) 4.1 (1.1–7.6) 3.0 (0–9) 3.8 (0.4–8.6)
BASMI – – 3 (0–10) – 3 (0–10)
DAS28 4.98 (2.6–7.3) – – 5.2 (3.1–7.3) 5.1(2.6–7.1)
PtGA 52 (5–98) 44 (2–96) 56 (6–96) 52 (2–96) 49 (6–98)
PGA 38 (7–73) 21 (0–57)¥ 26 (3–60)ф 38 (11–73) 27(0–73)*
MHAQ 0.65 (0–1.45) 0.40 (0.05–1.55) 0.43 (0–1.40) 0.45 (1–1.55) 0.50 (0–1.40)
Treatment, n (%)
Anti-TNF monotherapy 0 (0) 4 (14)¥ 20 (100)ɸ€ 0 24 (38)*
MTX monotherapy 34 (53) 15 (52) 0 (0)ɸ€ 49 (100) 0 (0)*
Anti-TNF ± MTX 30 (47) 10 (34) 0 (0) ɸ€ 0 (0) 40 (62)*
Beta-blockers 5 (8) 1 (3) 4 (20) 4 (8) 6 (9)
Calcium antagonists 5 (8) 2 (7) 2 (10) 2 (4) 7 (11)
ACE inhibitors 6 (9) 1 (3) 2 (10) 4 (8) 5 (8)
NSAIDs 47 (73) 14 (48)¥ 14 (70) 35 (71) 40 (62)
Coxibs 0 (0) 0 (0) 1 (5) 0 (0) 1 (2)
Statins 12 (19) 1 (3)¥ 7 (35)€ 7 (14) 13 (20)
Acetyl salicylic acid 6 (9) 2 (7) 3 (15) 6 (12) 5 (8)
Warfarin 0 (0) 0 (0) 1 (5)€ 0 (0) 1 (2)
Glucocorticoids 17 (27) 3 (10)¥ 2 (10)ɸ 8 (16) 15 (23)*
Unless indicated otherwise, values are given as median (range)
Statistically significant differences are shown in bold typeface
*P < 0.05, versus MTX
¥P < 0.05, versus RA
€P < 0.05, versus PsA
ФP < 0.05, versus RA
ACE angiotensin converting enzyme, anti-TNF antitumor necrosis factor, AS ankylosing spondylitis, BASDAI Bath Ankylosing Spondylitis Disease Activity Index, BASFI
Bath Ankylosing Spondylitis Functional Index, BASMI Bath Ankylosing Spondylitis Metrology Index, CRP C-reactive protein, DAS28 Disease activity score for 28
joints, ED endothelial dysfunction, ESR erythrocyte sedimentation rate, Ig immunoglobulin, MHAQ Medical Health Assessment Questionnaire, MTX methotrexate,
NSAID nonsteroidal anti-inflammatory drug, NSJ number of swollen joints, PGA Physicians' Global Assessment Score of Disease Activity, PsA psoriatic arthritis, PtGA
Patients' Global Assessment Score of Disease Activity, RA rheumatoid arthritis, RHI Reactive Hyperemic Index, WBC white blood cell
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Hypertension 17 (27) 7 (24) 6 (30) 9 (18) 21 (33)
BMI (kg/m2), median (range) 26 (19–41) 26 (19–39) 28 (22–36) 26 (20–39) 27 (20 – 41)
Hyperlipidemia 11 (17) 3 (10) 3 (15) 9 (18) 8 (12)
Current smokers 20 (31) 6 (21) 10 (50) 15 (31) 21 (33)
Family history of CVD or death 33 (52) 13 (45) 10 (50) 24(50) 32 (50)
Diabetes 3 (5) 0 (0) 1 (5) 0 (0) 4 (6)
Medical history
Previous myocardial infarction 5 (8) 0 (0) 2 (10) 2 (4) 5 (8)
Angina pectoris 2 (3) 1 (3) 2 (10) 2 (4) 3 (5)
Endothelial dysfunction
RHI, median (range) 1.89 (1.24–2.94) 2.06 (1.45–2.94) 1.81 (1.37–2.72)€ 1.93 (1.24–2.76) 1.82 (1.37–2.94)
ED 22 (34) 9 (31) 9 (45) 18 (37) 22 (34)
RHI, median (range) for patients with ED 1.47 (1.24–1.65) 1.56 (1.45–1.64) 1.52 (1.37–1.64) 1.49 (1.24–1.63) 1.52 (1.37–1.65)
Unless indicated otherwise, values are given as number (percentage)
Statistically significant differences are shown in bold typeface
€P < 0.05, versus PsA
anti-TNF antitumor necrosis factor, AS ankylosing spondylitis, BMI body mass index, CVD cardiovascular disease, ED endothelial dysfunction, MTX methotrexate, PsA
psoriatic arthritis, RA rheumatoid arthritis, RHI Reactive Hyperemic Index
Fig. 1 RHI values in RA, PsA, and AS patients with ED at all visits. *P < 0.05, versus baseline. The lines inside of the boxes show the median; the
whiskers of the boxes show upper and lower values. AS ankylosing spondylitis, IA inflammatory arthritis, PsA psoriatic arthritis, RA rheumatoid
arthritis, RHI Reactive Hyperemic Index
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Fig. 2 RHI values for patients with ED between and within the MTX and anti-TNF ± MTX groups. *P < 0.05 compared to baseline value. anti-TNF
anti-tumor necrosis factor, MTX methotrexate, ns not statistically significant, RHI Reactive Hyperemic Index
Table 3 Predictors of RHI change after 6 months of antirheumatic treatment in patients with ED
Unadjusted Adjusted
Beta P 95% CI Beta P 95% CI
Female gender 0.492 0.011 0.118 to 0.865 0.621 0.004 0.220 to 1.022
Age –0.004 0.669 –0.024 to 0.016 –0.001 0.919 –0.021 to 0.019
Anti-TNF ±MTX –0.505 0.008 –0.866 to –0.143 –0.448 0.032 –0.855 to –0.041
RDD –0.026 0.033 –0.049 to –0.002 –0.024 0.068 –0.050 to 0.002
PsA –0.067 0.779 –0.550 to 0.416 0.064 0.733 –0.386 to 0.514
AS –0.267 0.242 –0.722 to 0.188 0.219 0.419 –0.327 to 0.765
CRP –0.004 0.523 –0.017 to 0.009
ESR –0.002 0.771 –0.017 to 0.013
PTX3 –0.071 0.255 –0.194 to 0.053
PGA 0.008 0.160 –0.003 to 0.019
PtGA –0.001 0.824 –0.008 to 0.006
MHAQ –0.328 0.332 –1.006 to 0.349
NSJ –0.150 0.050 –0.299 to 0.000
Comparators: female gender versus male gender, anti-TNF ±MTX versus MTX monotherapy
Statistically significant differences are shown in bold typeface
anti-TNF anti-tumor necrosis factor, AS ankylosing spondylitis, CI confidence interval, CRP C-reactive protein, ESR erythrocyte sedimentation rate, MHAQ Medical
Health Assessment Questionnaire, MTX methotrexate, NSJ number of swollen joints, PGA Physicians' Global Assessment Score of Disease Activity, PsA psoriatic arthritis,
PtGA Patients' Global Assessment Score of Disease Activity, PTX3 pentraxin 3, RDD rheumatic disease duration, RHI Reactive Hyperemic Index
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Because MTX monotherapy was initiated only in
MTX-naive patients, and the combination therapy only
in patients who had previously used MTX without
sufficient effect, our findings may indicate that MTX treat-
ment in MTX-naive patients has a greater and more sus-
tained vasculoprotective effect than anti-TNF monotherapy,
or anti-TNF added to MTX treatment in MTX nonre-
sponders. It is likely that, in MTX nonresponders, MTX
also exhibited a poor response on disease activity after the
addition of anti-TNF (MTX in this group was provided first
of all to reduce side-effects of anti-TNF therapy). One might
speculate that the poor response of MTX on inflammation
is associated also with a poor effect on EF.
The exact mechanism behind the protective effect of
antirheumatic treatment on ED is not known [25]. The-
oretically, it might be mediated by inhibition of systemic
inflammatory factors and the corresponding metabolic
abnormalities. However, this explanation is not sup-
ported by our findings since the improvement in RHI
was not related to systemic markers of disease activity,
such as ESR and CRP. Moreover, we did not find any
significant relationships between RHI levels and inflam-
matory markers at baseline.
Another explanation might be that the examined drugs
might have a direct beneficial effect on the vessel walls, in-
cluding the endothelium. It has been shown that MTX
and anti-TNF treatments are associated with improve-
ments in reverse cholesterol transport by various mecha-
nisms [26, 27]. For example, MTX increases high-density
lipoprotein (HDL) capacity to promote cholesterol efflux
from cells [28]. Anti-TNF agents counteract the deleteri-
ous effects of TNF on the expression of genes involved in
cholesterol efflux and reduce cell cholesterol accumula-
tion through amelioration of serum lipoprotein functions
and through reverse signaling following direct interaction
with cell membrane-bound TNF [26].
Although most focus has been on the importance of
impaired cell cholesterol efflux in the development of
foam cells from macrophages in atherosclerotic plaques,
the same mechanism may also underlie disturbances in
endothelial cells, with reduction of their vasodilating and
anti-inflammatory functions [29]. In fact, increased chol-
esterol efflux through the membrane transporters ATP-
binding cassette A1 and G1 and Scavenger Receptor
class B type I in endothelial cells is associated with
promotion of eNOS expression and PGI2 production
[30–32]. Moreover, serum HDL capacity to promote cell
cholesterol efflux is directly correlated to flow mediated
dilation [33]. Thus, the improved cell cholesterol efflux
due to antirheumatic treatment might both protect from
atheroma formation and from ED.
IA patients have been reported to have more inflam-
mation, involving overexpression of TNF, in their vascu-
lar media and adventitia compared to non-IA patients
with CVD [34, 35]. It might even be that inflammation
located in deep vascular layers might affect the luminal
part of the artery, including the phenotype of the endo-
thelial cells [36]. Thus, in theory, antirheumatic treat-
ment, such as anti-TNF, could also ameliorate EF by
inhibition of vascular inflammation.
ED occurs when the endothelium is activated and is
characterized by cytokine production, loss of vascular in-
tegrity, and expression of adhesion molecules [37].
Adhesion molecules such as intercellular adhesion mol-
ecule (ICAM)-1, E-selectin, and vascular cell adhesion
molecule (VCAM)-1 make the endothelium surface
more adhesive to leukocytes and facilitate their migra-
tion into the vessel wall (including atherosclerotic
lesions) [37, 38].
In keeping with our results, both MTX and anti-TNF
have been previously reported to downregulate expres-
sion of adhesion molecules on endothelial cells, i.e.,
circulating markers of ED [39–43]. Also, a recent review
and meta-analysis article concluded that anti-TNF treat-
ment might improve EF in RA patients [44].
Our previous article based on the same patient sample
demonstrated that MTX and anti-TNF ±MTX treatment
significantly reduced inflammatory activity (determined
by ESR, CRP, WBC count, PGA, and PtGA) both at
6 weeks and at 6 months compared to baseline [16].
This may indicate that both treatment regimens have a
longstanding effect on inflammation, but only MTX (in
patients potentially responding to it) has a prolonged
beneficial effect on the endothelial cells.
We cannot definitely rule out the possibility that the
observed differences in the effect of the antirheumatic
treatments on EF might be based on differences in
patient populations or other factors. For example, it might
be that patients with longer and more therapy-resistant IA
(i.e., features typical for the anti-TNF ±MTX group;
Table 1) had a higher CV risk and were less likely to im-
prove their EF by antirheumatic treatment than the
remaining IA patients (Table 2). Nevertheless, the differ-
ences in RHI change between baseline and 6 months in
the two treatment groups were independent of rheumatic
disease duration, IA diagnosis, and age. Moreover, there
were no statistically significant differences in the examined
traditional CV risk factors, the occurrences of clinical
CVD and ED, and median RHI values at baseline between
the two treatment groups (Table 2).
As different immune and other mechanisms are in-
volved in the pathogenesis of RA, PsA, and AS, it might
be that ED in these diseases is also mediated partly by
different factors. Consequently, the effect of different an-
tirheumatic drugs on ED in these particular diseases
might also be different.
When comparing the three diagnostic groups, the AS
group were the most likely to have ED and CV comorbidity
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(Table 2), in spite of being younger, having a similar disease
duration as the RA and PsA groups, and being less likely to
use systemic glucocorticoids than the RA group (Table 1).
It is possible that the increased occurrence of certain CV
risk factors, such as a high proportion of men and smokers,
could partly explain the impaired EF in the AS group [45].
The improvements in RHI from baseline to 6 weeks and
6 months were apparent in all diagnostic groups, but it
was statistically significant only in the total IA and in the
RA group. The lack of statistically significant differences
in RHI improvement in the other groups might be due to
their relatively low sample size. Indeed, other studies
indicate that antirheumatic treatment (anti-TNF) also
improves EF in patients with PsA and AS [46, 47]. We
cannot exclude the possibility that AS patients experi-
enced less protection from antirheumatic treatment be-
cause they were treated only with anti-TNF and not MTX.
The cause of the observed decreased effect of
anti-TNF on EF at 6 months is unclear. Among other
factors, it might be caused by the well-known secondary
nonresponse effect due to the development of antidrug
antibodies [48].
Interestingly, women had statistically greater RHI im-
provement after 6 months of treatment than men
(Table 2). Thus, our results may indicate that women
have a better ability to reverse ED than men, independ-
ently of IA diagnosis, when treated with MTX or
anti-TNF ±MTX. We do not know the molecular mech-
anism behind this phenomenon.
Rheumatic disease duration showed a stable negative
association with RHI change from baseline to 6 months
in several multiple regression models. It seems more dif-
ficult to achieve an EF improvement in patients with
longer rheumatic disease duration, and this applies for
both treatment regimens. Thus, these data support the
notion that early antirheumatic treatment is important
not only for prevention of joint damage, but also for
protection from atherosclerosis. However, our results
have to be confirmed in larger studies.
As in most studies, ours has several limitations. First,
due to ethical reasons (to avoid prescribing MTX to pa-
tients in need of anti-TNF, and to avoid overtreatment
in patients that might be sufficiently treated with MTX
monotherapy) we conducted an observational study in-
stead of a randomized controlled trial (RCT). Thus, we
could not secure the same level of similarity between
study groups at baseline as in a RCT, nor conduct
double-blinded evaluation. On the other hand, observa-
tional studies have other advantages, e.g., they can more
accurately reflect real life, and therefore have increas-
ingly been called for over the last years. To compen-
sate for baseline differences between the groups, we
adjusted for several baseline characteristics in multiple
regression models.
As MTX is the drug of choice in most patients with
peripheral chronic arthritis, patients with these condi-
tions who receive anti-TNF treatment are likely to have
a longer and more severe IA. Nevertheless, the anti-TNF
group did not differ from the MTX group when compar-
ing several disease activity markers. In fact, the MTX
group had statistically significantly higher PGA scores
than the anti-TNF ±MTX group (Table 1).
Second, we were not able to evaluate differences in
monotherapies with MTX and anti-TNF as most of the
patients using anti-TNF also used MTX comedication.
Third, we evaluated RHI change only in patients with
ED because we could not expect substantial RHI im-
provement in patients with normal EF. Therefore,
regression to the mean might be questioned. However,
in contrast to patients with low RHI, RHI mean values
in patients with normal EF did not change towards the
RHI mean at any of the control points of time. Taken
together, these observations diminish the suspicion that
the observed RHI differences in the ED group could be
explained by regression to the mean only.
Finally, owing to a relatively small sample size, the ap-
parent lack of some differences and associations may be
due to type II errors and insufficient statistical power.
Still, as this is to our knowledge the first study compar-
ing the effect of MTX and anti-TNF regimens in IAs on
EF, and comparing EF in RA, PsA, and AS, it brings new
important insights into CVD in IAs, and indicates the
need for further research.
An advantage of our study is a well-characterized
study sample, and a design that makes it possible to
examine the effect of two of the main antirheumatic
treatment regimens on EF in three common IAs.
Conclusions
In conclusion, treatment with MTX and anti-TNF ±MTX
appears to improve EF relatively quickly in IA patients with
ED. After 6 months, the EF improvement was more pro-
nounced in the MTX users than in the anti-TNF ±MTX
users. Among other factors, this might be due to a more
sustained beneficial effect of MTX on the vasculature.
Because the EF improvement was independent of im-
provement in rheumatic disease activity, modes of action
other than the anti-inflammatory effect might play a role.
Among patients with active RA, AS, and PsA, those
with AS had the worst endothelial function (the differ-
ence was statistically significantly different compared to
those with PsA), although they were the youngest.
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